Drug intelligence / Profile preview

GAPTX

Development stage: Preclinical
Lead developer: CSR Pharma Group

Overview

GAPTX (Genome-Associated Precision Therapies) is a preclinical-stage precision medicine platform developed by CSR Pharma Group in collaboration with Rutgers University. The platform is designed to identify and target specific cancer epitopes, with a primary focus on glioblastoma (GBM) brain cancers and other advanced or metastatic diseases. The technology incorporates an exclusive global license from Harvard University for a novel cancer epitope and has been expanded through discovery technology acquisitions. GAPTX aims to leverage genomic data to develop personalized therapeutic interventions for brain cancers.

Other names: Genome-Associated Precision Therapies

Beyond the preview

Go deeper on GAPTX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAPTX.

Explore the full profile